Predictive Biosciences Raises $25M in Series C Funding Round
June 18, 2010
Predictive Biosciences Raises $25M in Series C Funding Round
The proceeds will be used to complete multi-center trials for Predictive's CertNDx bladder cancer diagnostic and for the commercial launch of the test through its CLIA certified laboratories, the company said in a statement.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Oligo-Based Protein Capture Tools Allow Simultaneous Reporting of Genetic, Proteomic Biomarker Data
October 21, 2011 / ProteoMonitor - People in the News: Eric Bouvier; Alan Marshall; and More
January 13, 2012 / ProteoMonitor - Proteomics Technologies Making Their Way into Pathogen Detection
August 19, 2011 / ProteoMonitor - Pressure BioSciences Q2 Revenues Plunge 53 Percent; Enough Capital to Last until Mid-September
August 16, 2011 / GenomeWeb Daily News - People In The News
July 1, 2011 / GenomeWeb Daily News